Dicerna Pharmaceuticals Profit Margin

Dicerna Pharmaceuticals (DRNA) currently reports a profit margin of -64.53% as of September 2021. That compares with -88.81% in the prior-year period — up 27.3% year over year. That is below the Healthcare sector average of 13.76%. Use the charts on this page to explore Dicerna Pharmaceuticals's profit margin history and peer comparisons.

Dicerna Pharmaceuticals's profit margin increased from -88.81% to -64.53% — a 27.3% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dicerna Pharmaceuticals's profit margin of -64.53% is lower than the Healthcare sector average of 13.76%. That is roughly 568.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Dicerna Pharmaceuticals's current -64.53% should be judged against Healthcare norms (sector average: 13.76%) and against DRNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -64.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.